Mechanistic and pharmacological issues of aspirin as an anticancer agent.
about
Toll-like receptors and cancer, particularly oral squamous cell carcinoma.Apoptotic effects of two COX-2 inhibitors on breast adenocarcinoma cells through COX-2 independent pathway.Two COX-2 inhibitors induce apoptosis in human erythroleukemia K562cells by modulating NF-κB and FHC pathways.NSAIDs: learning new tricks from old drugsRole of platelets in inflammation and cancer: novel therapeutic strategies.The aspirin metabolite salicylate inhibits lysine acetyltransferases and MUC1 induced epithelial to mesenchymal transition.Aspirin therapy reduces the ability of platelets to promote colon and pancreatic cancer cell proliferation: Implications for the oncoprotein c-MYC.Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer.Proteome-wide prediction of targets for aspirin: new insight into the molecular mechanism of aspirin.Therapeutic dosages of aspirin counteract the IL-6 induced pro-tumorigenic effects by slowing down the ribosome biogenesis rate.Use of Cyclo-Oxygenase Inhibitors Is Not Associated with Clinical Relapse in Inflammatory Bowel Disease: A Case-Control Study.Acetyl salicylic acid attenuates cardiac hypertrophy through Wnt signaling.Salicylic acid metabolites and derivatives inhibit CDK activity: Novel insights into aspirin's chemopreventive effects against colorectal cancer.Platelet count as a predictor of metastasis and venous thromboembolism in patients with cancer.Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action.A Temporal Examination of Platelet Counts as a Predictor of Prognosis in Lung, Prostate, and Colon Cancer Patients.Personalized regulation of glioblastoma cancer stem cells based on biomedical technologies: From theory to experiment (Review).
P2860
Q34239239-AE09196E-8466-4946-A4D9-6D6D44439781Q35228956-7C60A70F-C389-45E0-8E8C-CA94E23F50B3Q36439206-28FDE7C2-F235-4945-BF8B-96B47A7CD27CQ37341156-9E765DD2-EB5F-43C2-9044-FB507B315EF3Q38151957-EEDCE656-ED19-4EF6-9853-5AFB4854FB78Q38697027-BC7E1EE2-3957-45EF-824E-291A3EF5E77BQ38728228-67A06299-AC31-40E9-80C5-447BD253EBE8Q38745843-B50BEF6B-213D-4B83-A058-4B214A9958A9Q39028044-B8D658B3-34D0-4119-ABAD-F3E159AD6392Q39457252-736EC7F6-3280-4624-B2DC-95A87A5ACEF8Q41610897-8907A1D5-D894-452B-908B-736CC7729F2CQ46260161-86A23916-348C-4C90-B245-A2E3D3A1CE1AQ47168447-D305831A-81D9-4696-8D86-84A4A46C09D8Q47400340-2C950E38-D16B-40F1-8EDF-E4BBBE45DF47Q51073878-F9385F77-2A51-467B-B594-A87BD411F17CQ54936867-2C9D4BAE-6A0B-4AF8-A717-3D8995DC60DBQ55509415-8A6DF797-CEAA-4332-93FB-66B580595B29
P2860
Mechanistic and pharmacological issues of aspirin as an anticancer agent.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 December 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mechanistic and pharmacological issues of aspirin as an anticancer agent.
@en
Mechanistic and pharmacological issues of aspirin as an anticancer agent.
@nl
type
label
Mechanistic and pharmacological issues of aspirin as an anticancer agent.
@en
Mechanistic and pharmacological issues of aspirin as an anticancer agent.
@nl
prefLabel
Mechanistic and pharmacological issues of aspirin as an anticancer agent.
@en
Mechanistic and pharmacological issues of aspirin as an anticancer agent.
@nl
P2093
P2860
P356
P1433
P1476
Mechanistic and pharmacological issues of aspirin as an anticancer agent.
@en
P2093
Carlos Sostres
Emanuela Ricciotti
Paola Patrignani
Stefania Tacconelli
P2860
P304
P356
10.3390/PH5121346
P577
2012-12-05T00:00:00Z